Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182376 | 0.87 | — | — | |
| SCHEMBL4572656 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| SCHEMBL4572657 | 0.77 | CHRNB2 (0.38) | CHRNB2CHRNA4LMNACHRM2CHRM4 | |
| SCHEMBL4572645 | 0.76 | FFAR1 (0.36) | CHRNB2CHRNA4LMNATHRBALDH1A1 | |
| SCHEMBL12283650 | 0.70 | — | — | |
| SCHEMBL22563213 | 0.69 | — | — | |
| Oxalic Acid SCHEMBL9559839 | 0.69 | CHRNB2 (0.37) | CHRNB2CHRNA4LMNACHRM2CHRM4 | |
| SCHEMBL7837916 | 0.66 | INMT (0.33) | BRD4BRD2 | |
| SCHEMBL7831654 | 0.66 | — | — | |
| SCHEMBL13947189 | 0.65 | CHRNB2 (0.37) | CHRNB2CHRNA4LMNACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445874-B1 | PROCESS OF PREPARATION OF 2-ACETYL-1-PYRROLINE AND A STABLE PRECURSOR THEREOF, ISOTOPICALLY LABELLED OR NOT | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-11-29 | — | — | EP | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | UNIVERSITE DE MONTPELLIER (FR) | 2012-04-26 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CHRNB2 476/4885CHRNA4 615/4885BRD4 2425/4885 |
| US-20120100274-A1 | METHOD FOR SYNTHESISING 2-ACETYL-1-PYRROLINE AND THE STABLE PRECURSOR THEREOF, OPTIONALLY ISOTOPICALLY MARKED | SAT1, PDHA1, PTMS | CHRNB2 1454/4885CHRNA4 1215/4885BRD4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.